Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment Nipocalimab, a novel treatment developed by Johnson & Johnson, has received Fast Track designation from the FDA for lupus therapy, addressing critical patient needs.

Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Systemic_Lupus

Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab Johnson & Johnson has announced promising Phase 2 results for nipocalimab, the first investigational FcRn blocker aimed at treating systemic lupus erythematosus.

Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab #USA #Johnson_&_Johnson #Spring_House #nipocalimab #Systemic_Lupus_Erythematosus

Emerging FcRN Blockade May Transform Management of FNAIT Intravenous immunoglobulin remains the standard of care for preventing thrombocytopenia and intracranial hemorrhage in FNAIT.

#Nipocalimab, a monoclonal antibody that inhibits the neonatal FcRN, has shown early therapeutic potential in FNAIT, a rare antibody-mediated disorder of #pregnancy. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4i7aoTc

#MedNews - The FcRn blocker #nipocalimab significantly improves clinical disease activity in people with moderate-to-severe #SjögrenDisease and could be a promising approach for these patients.

Full story 👉 buff.ly/e8cj9Jw

#RheumSky

Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study Recent findings reveal that nipocalimab significantly reduced disease activity in patients with Sjögren's disease, showcasing its potential as a transformative therapy.

Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Sjögren's_Disease

FREESIA-3 Study Adds First US Site The study is recruiting up to 50 participants to assess the efficacy and safety of nipocalimab in reducing the risk of severe FNAIT.

Philadelphia @pennmedicine.bsky.social has been added as a site for the #FREESIA3 trial investigating #Nipocalimab vs intravenous immunoglobulin (#IVIG) in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (#FNAIT).

Read more: https://bit.ly/4mZjRhb

#RareSky #MedSky

Johnson & Johnson Unveils Long-Term Efficacy Data for Nipocalimab in Myasthenia Gravis Treatment New findings from Johnson & Johnson demonstrate that nipocalimab offers sustained disease control in adults with generalized myasthenia gravis, showcasing improvements and reduced antibody levels over 18 months.

Johnson & Johnson Unveils Long-Term Efficacy Data for Nipocalimab in Myasthenia Gravis Treatment #United_States #Johnson_&_Johnson #nipocalimab #Myasthenia_Gravis #Spring_House,_Pennsylvania

Exciting New Findings on Nipocalimab: Promising Phase 3 Results and Insights for Myasthenia Gravis at AAN 2025 Recent data presented at AAN 2025 showcased nipocalimab's positive Phase 3 results, promising sustained control in myasthenia gravis patients, addressing crucial healthcare gaps.

Exciting New Findings on Nipocalimab: Promising Phase 3 Results and Insights for Myasthenia Gravis at AAN 2025 #United_States #San_Diego #Johnson_&_Johnson #nipocalimab #Myasthenia_Gravis

Nipocalimab: Pioneering Advancement in Sjögren's Disease Treatment Receives Fast Track Designation Nipocalimab, a groundbreaking treatment for Sjögren's disease, gains Fast Track designation by the FDA, paving the way for new therapeutic options.

Nipocalimab: Pioneering Advancement in Sjögren's Disease Treatment Receives Fast Track Designation #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Sjögren's_Disease

Latest Insights on Nipocalimab Reveal Potential for Treating IgG-Driven Autoantibody Diseases New findings on nipocalimab highlight its potential as a treatment for IgG-driven diseases. The research details its unique binding properties and clinical implications.

Latest Insights on Nipocalimab Reveal Potential for Treating IgG-Driven Autoantibody Diseases #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Autoantibody_Diseases

#Nipocalimab, an immunoselective #FcRn blocker that lowers #IgG and has unique molecular properties

#autoimmunity #alloimmunity #therapeuticantibodies

Breaking study from @johnsonandjohnson.bsky.social

www.tandfonline.com/doi/full/10....

Nipocalimab Phase 3 Study Results Published in The Lancet Neurology for gMG Patients The Lancet Neurology reveals pivotal Phase 3 study results of nipocalimab, highlighting its effectiveness for generalized myasthenia gravis.

Nipocalimab Phase 3 Study Results Published in The Lancet Neurology for gMG Patients #USA #Spring_House #nipocalimab #Myasthenia_Gravis #JNJ

Nipocalimab Achieves Priority Review from U.S. FDA for Myasthenia Gravis Treatment Johnson & Johnson's nipocalimab has received Priority Review from the U.S. FDA, aiming to provide new treatment options for generalized myasthenia gravis, a serious condition.

Nipocalimab Achieves Priority Review from U.S. FDA for Myasthenia Gravis Treatment #United_States #Spring_House #nipocalimab #Myasthenia_Gravis #J&J

New Insights into Warm Autoimmune Hemolytic Anemia from Johnson & Johnson's ASH 2024 Presentation Johnson & Johnson has provided critical insights into the severe impact of warm autoimmune hemolytic anemia, highlighting the urgent need for targeted treatments.

New Insights into Warm Autoimmune Hemolytic Anemia from Johnson & Johnson's ASH 2024 Presentation #United_States #San_Diego #Johnson_&_Johnson #Autoimmune_Anemia #nipocalimab